Acta dermato-venereologica最新文献_第5页

Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-06 DOI: 10.2340/actadv.v105.41298

Natalia Kirsten, Matthias Augustin, Christine Blome, Janine Topp, Richard Schwager, Falk G Bechara, Gefion Girbig, Andreas Pinter, Florian Anzengruber, Mareen Lindegaard, Christos C Zouboulis, Marina Otten

{"title":"Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS.","authors":"Natalia Kirsten, Matthias Augustin, Christine Blome, Janine Topp, Richard Schwager, Falk G Bechara, Gefion Girbig, Andreas Pinter, Florian Anzengruber, Mareen Lindegaard, Christos C Zouboulis, Marina Otten","doi":"10.2340/actadv.v105.41298","DOIUrl":"10.2340/actadv.v105.41298","url":null,"abstract":"Hidradenitis suppurativa is a chronic skin disease associated with significant disease burden. To assess patients' treatment benefits, disease-specific outcomes measurement is needed. This study aimed to develop a questionnaire called Patient Benefit Index for hidradenitis suppurativa (PBI-HS). After an open-item survey, the items were condensed into a 26-item questionnaire on patient needs and benefits, with a 5-point Likert scale. In the validation study, construct and content validity, responsiveness, and feasibility of the questionnaire were assessed at 2 time points. A 26-item questionnaire was created following open-item generation by n = 72 patients. In the validation study, 3 items perceived as most relevant by patients were: \"to be free of pain\" (mean: 3.6 on a scale of 0-4), \"to be free of inflammation\" (mean: 3.6), \"to have no more scars\" (mean: 3.1). Significant correlations of PBI-HS at follow-up visit were found with the physical global assessment for hidradenitis suppurativa (HS-PGA) (r = -0.471; p = 0.000), number of inflammatory lesions (r = -0.359; p = 0.005), and DLQI (r = -0.383; p = 0.003), indicating less disease burden in patients with higher treatment benefits. The PBI-HS is a feasible and valid instrument to assess patient-reported treatment benefits in hidradenitis suppurativa.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv41298"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Definition of the Concept of Super-responders in Atopic Dermatitis: A Spanish Delphi Consensus.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-06 DOI: 10.2340/actadv.v105.42240

Juan-Manuel Liñán-Barroso, Juan-Carlos Hernández-Rodríguez, Ricardo Ruiz-Villaverde, Manuel Galán Gutiérrez, Francisco Navarro-Triviño, Javier Domínguez Cruz, José-Carlos Armario-Hita, Jose-Juan Pereyra-Rodriguez

{"title":"Definition of the Concept of Super-responders in Atopic Dermatitis: A Spanish Delphi Consensus.","authors":"Juan-Manuel Liñán-Barroso, Juan-Carlos Hernández-Rodríguez, Ricardo Ruiz-Villaverde, Manuel Galán Gutiérrez, Francisco Navarro-Triviño, Javier Domínguez Cruz, José-Carlos Armario-Hita, Jose-Juan Pereyra-Rodriguez","doi":"10.2340/actadv.v105.42240","DOIUrl":"10.2340/actadv.v105.42240","url":null,"abstract":"A consensus study of experts was conducted to establish a definition of the concept of super-responders (SR) in atopic dermatitis (AD). The study employed a Delphi methodology based on 2 rounds to define the concept of SR in AD, exploring the opinions of expert dermatologists in AD from across Spain regarding a series of statements developed after a systematic review. Consensus was predefined as an agreement of ≥ 80% among all respondents. In the first round, 4 statements reached consensus. In the second round, 2 additional statements reached consensus. To illustrate these definitions, a set of practical cases was provided, and the level of agreement among experts was evaluated. According to the agreed statements, time is important when defining the achievable response as SR. The concept of SR should associate a rapid response (before week 16), include both symptom variables, such as the Eczema Area and Severity Index and Investigators Global Assessment (IGA) and patient-reported outcomes, including pruritus or the Patient-Oriented Eczema Measure. This concept should be associated with complete or nearly complete clearance of lesions (IGA 0-1), and with sustained responses over time (at week 52). Mild flares (IGA ≤ 2) may occur without varying according to the patient's age.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42240"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple Erythematous Annular Scaly Plaques: A Quiz.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-03 DOI: 10.2340/actadv.v105.42771

Masahiro Oka

引用次数: 0

Identification of Stigmatization and Relevant Predictors in People with Alopecia Areata and Androgenetic Alopecia: A Comparative Cross-sectional Study in German-speaking Countries and the USA.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-03 DOI: 10.2340/actadv.v105.42278

Johaina Kullab, Caroline F Z Stuhlmann, Stefanie Ziehfreund, Hannah Wecker, Tilo Biedermann, Alexander Zink

{"title":"Identification of Stigmatization and Relevant Predictors in People with Alopecia Areata and Androgenetic Alopecia: A Comparative Cross-sectional Study in German-speaking Countries and the USA.","authors":"Johaina Kullab, Caroline F Z Stuhlmann, Stefanie Ziehfreund, Hannah Wecker, Tilo Biedermann, Alexander Zink","doi":"10.2340/actadv.v105.42278","DOIUrl":"10.2340/actadv.v105.42278","url":null,"abstract":"Stigmatization of skin conditions like alopecia areata (AA) and androgenetic alopecia (AGA) impairs quality of life (QoL), but research is limited. The aim of this study was to compare stigmatization and QoL in individuals with AA and AGA in German-speaking (GS) and US samples and identify stigmatization predictors. This cross-sectional online survey included AA and AGA participants from GS countries (April-August 2020) and the USA (May-August 2021). Stigmatization and QoL were assessed using the Perceived Stigmatization Questionnaire (PSQ) and Hairdex, along resilience, happiness, and social support assessment tools. Regression analyses evaluated disease severity, duration, age, gender, marital status, and social support as stigmatization predictors. All subgroups perceived stigmatization and impaired QoL. GS-AA (n = 423, 93.6% women) participants perceived more stigma but better QoL than GS-AGA (n = 102, 79.4% women). The US sample (AA: n = 199, 84.4% women; AGA: n = 47, 93.6% women) showed similar trends, though insignificant. GS participants reported higher stigma and US participants lower QoL. Stigmatization was associated with being male, younger, employed, severe disease, daily-life restrictions, and anxiety. Both samples were predominantly female, with the US sample being older and smaller, potentially reducing significance. In conclusion, sociodemographics and gender influence stigmatization and QoL. Interventions should enhance resilience and social support.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42278"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-03 DOI: 10.2340/actadv.v105.42572

Johan Sieborg, Julia-Tatjana Maul, Jashin J Wu, Nikolai Nguyen Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Tomas Norman Dam, Trine Bertelsen, Kawa Khaled Ajgeiy, Simon Francis Thomsen, Jacob P Thyssen, Alexander Egeberg, David Thein

{"title":"Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.","authors":"Johan Sieborg, Julia-Tatjana Maul, Jashin J Wu, Nikolai Nguyen Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Tomas Norman Dam, Trine Bertelsen, Kawa Khaled Ajgeiy, Simon Francis Thomsen, Jacob P Thyssen, Alexander Egeberg, David Thein","doi":"10.2340/actadv.v105.42572","DOIUrl":"10.2340/actadv.v105.42572","url":null,"abstract":"Biosimilars are designed to be analogous to the biologic originators. However, comprehensive comparisons between biosimilars are limited and lacking for patients with psoriasis. This study's objective was to compare 1-year drug survival of the 2 adalimumab biosimilars, GP2017 with SB5, following a non-medical mandatory switch from the adalimumab originator. Based on the national clinical database DERMBIO, this nationwide cohort study included all patients with psoriasis treated with the adalimumab originator who underwent a non-medical mandatory switch to GP2017 or SB5. The study included 525 patients switching from adalimumab originator to 1 of 2 biosimilars: GP2017 (n=267 patients) or SB5 (n=258 patients). When comparing the drug survival of the biosimilars, the hazard ratio was 1.11 (95% confidence interval, 0.58-2.12) for SB5 with GP2017 as reference. In the sensitivity analysis investigating changes in PASI, no differences were found when comparing the GP2017 group and the SB5 group at 120 days of follow-up (1.9% vs 1.6% improved, 1.9% vs 2.0% worsened, and 43.1% vs 40.9% remained unchanged). When comparing GP2017 and SB5, no discernible differences were found in drug survival or effectiveness based on PASI. Determining drug survival and effectiveness could benefit patients and clinicians in treatment decisions.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42572"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introducing Social Dermatology.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-03 DOI: 10.2340/actadv.v105.42622

Elisabeth M M Christensen, Gregor Jemec, Ditte Marie L Saunte, Ole Steen Mortensen

{"title":"Introducing Social Dermatology.","authors":"Elisabeth M M Christensen, Gregor Jemec, Ditte Marie L Saunte, Ole Steen Mortensen","doi":"10.2340/actadv.v105.42622","DOIUrl":"10.2340/actadv.v105.42622","url":null,"abstract":"Increasing evidence supports the idea that social determinants of health, e.g., educational attainment, employment, and community context, directly affect health status. Researchers are also beginning to explore the impact of social factors on skin diseases, though no formalized research field, to the authors' knowledge, provides a structured framework for such practice. In this article, the novel global research field of \"Social Dermatology\" is introduced to structure academic knowledge in dermatology. The aim is to outline how this paradigm shift could transform both clinical practice and scientific research. The field will explore subjects studied within the medical field of Social Medicine, adapting and applying them to the context of dermatology. Specifically the article will address the social determinants of health in dermatology, and elaborate on human functioning as an approach to a more comprehensive understanding of health in people with skin diseases. This approach enables the integration of rehabilitative aspects, with the International Classification of Functioning (ICF) guiding research and clinical practice to promote more equitable and patient-centred care. To address methodological and communicative opportunities it is suggested that a theoretical web-based social incubator be developed. A formal agreement on the values, interests, and challenges of this new field is needed for a sustainable research effort.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42622"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-03 DOI: 10.2340/actadv.v105.42081

Jiaying Li, Xin Xiang, Zhaoyang Wang, Chaoyang Miao, Yunliu Chen, Zigang Xu

{"title":"Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.","authors":"Jiaying Li, Xin Xiang, Zhaoyang Wang, Chaoyang Miao, Yunliu Chen, Zigang Xu","doi":"10.2340/actadv.v105.42081","DOIUrl":"10.2340/actadv.v105.42081","url":null,"abstract":"Current guidelines recommend psoriatic patients with latent tuberculosis infection undergo chemoprophylaxis prior to initiating any biologic. However, clinical studies indicate that interleukin (IL) inhibitors may not increase the risk of tuberculosis reactivation. This review evaluates the safety in psoriatic patients with latent tuberculosis infection using IL inhibitors without chemoprophylaxis. PubMed and EMBASE were searched up to 1 November 2024 in accordance with PRISMA. Fifteen studies, including one safety analysis of a clinical trial, 2 case series, and 12 retrospective studies were analysed. The included studies reported a total of 837 cases: 179 patients were treated with secukinumab, 69 with ixekizumab, 8 with brodalumab, 539 with risankizumab, 22 with guselkumab, and 20 with tildrakizumab. Psoriatic patients with latent tuberculosis infection using an IL-12/23 inhibitor without chemoprophylaxis were not found in this review. Three of the 837 cases exhibited reactivation of tuberculosis. The reactivation rate is 0.78% among psoriatic patients with latent tuberculosis infection using IL-17 inhibitors, and 0.17% among those using IL-23 inhibitors. Our analysis shows that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis activation in psoriatic patients with latent tuberculosis infection. The impact of IL-12/23 inhibitors on tuberculosis reactivation among psoriatic patients with latent tuberculosis infection remains uncertain and requires further investigation.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42081"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seasonal Changes in the Severity of Atopic Dermatitis by Birth Season: A Pilot Prospective Cohort Study.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-03 DOI: 10.2340/actadv.v105.41987

Yu-Ting Zhang, Hong-Min Li, Yi-Jin Zhang, Cheng Tan, Bo Xie

引用次数: 0

Novel Detection and Clinical Utility of Serum-Derived Extracellular Vesicle in Angiosarcoma.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-02-25 DOI: 10.2340/actadv.v105.40902

Kazunori Yokoi, Jing Wang, Yusuke Yoshioka, Yasuhiro Fujisawa, Manabu Fujimoto, Takahiro Ochiya, Atsushi Tanemura

{"title":"Novel Detection and Clinical Utility of Serum-Derived Extracellular Vesicle in Angiosarcoma.","authors":"Kazunori Yokoi, Jing Wang, Yusuke Yoshioka, Yasuhiro Fujisawa, Manabu Fujimoto, Takahiro Ochiya, Atsushi Tanemura","doi":"10.2340/actadv.v105.40902","DOIUrl":"10.2340/actadv.v105.40902","url":null,"abstract":"Cutaneous angiosarcoma is a rare and highly aggressive skin malignancy. The aim of this study is to explore the alteration of serum-derived extracellular vesicle (EV) in angiosarcoma patients and to evaluate its clinical utility as a novel circulating biomarker. In a microarray analysis to examine the differential expression of specific EV-associated microRNAs in sera between cutaneous angiosarcoma patients and healthy controls, 73 microRNAs with significant upregulation and 100 microRNAs with significant downregulation, respectively, were identified in patients with angio-sarcoma. Among them, quantitative PCR confirmed that miR-184, miR-3925-5p, miR-3926, and miR-5703 were upregulated in sera of cutaneous angiosarcoma patients compared with those of healthy controls and melanoma patients. Additionally, these 4 microRNAs were expressed more highly in angiosarcoma cell lines compared with normal human endothelial cell lines and were prone to elevate along with disease progression. Furthermore, a gene analysis predicted that the target gene set of microRNAs might affect the regulation of TP53 via the epigenetic regulation of MECP2. Taken together, these 4 extracellular vesicle-associated microRNAs in circulation serve as a promising liquid biomarker to identify angiosarcoma patients and trace disease progression.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv40902"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma Diagnosis in the Post-COVID-19 Era: Return to "Normality" only in 2023 in 2 German Skin Tumour Centers.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-02-25 DOI: 10.2340/actadv.v105.42863

Peter Mrotzek, Silke C Hofmann, Alexander Kreuter, Sebastian Appelbaum, Ulrich Wesselmann, Ulrich Peter Wehry, Galina Balakirski

引用次数: 0